{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:10:13Z","timestamp":1788930613116,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004621","name":"Kerman University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03339-x","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:46:48Z","timestamp":1784263608000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Methanolic extract of Zataria multiflora and arsenic trioxide combination therapy modulates oncogenic and tumor suppressor MicroRNA expression and RAF1 signaling in NB4 acute promyelocytic leukemia cells"],"prefix":"10.1007","volume":"43","author":[{"given":"Mahsa","family":"Asghari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Afgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajar Mardani","family":"Valandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Mohammad","family":"Zahedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Farsinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Ehsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hossein","family":"Ashoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roohollah Mirzaee","family":"Khalilabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"1","key":"3339_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12885-023-10612-z","volume":"23","author":"H Gill","year":"2023","unstructured":"Gill H, Raghupathy R, Lee CY, Yung Y, Chu H-T, Ni MY, et al. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021. BMC Cancer. 2023;23(1):141.","journal-title":"BMC Cancer"},{"issue":"13","key":"3339_CR2","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.3390\/cancers15133477","volume":"15","author":"J Hermsen","year":"2023","unstructured":"Hermsen J, Hambley B. The coagulopathy of acute promyelocytic leukemia: an updated review of pathophysiology, risk stratification, and clinical management. Cancers. 2023;15(13):3477.","journal-title":"Cancers"},{"issue":"23","key":"3339_CR3","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.3390\/cancers16234092","volume":"16","author":"A Bidikian","year":"2024","unstructured":"Bidikian A, Bewersdorf JP, Kewan T, Stahl M, Zeidan AM. Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them. Cancers. 2024;16(23):4092.","journal-title":"Cancers"},{"issue":"3","key":"3339_CR4","first-page":"53","volume":"3","author":"Z Yan","year":"2024","unstructured":"Yan Z. A review of arsenic trioxide in the treatment of acute promyelocytic leukemia: clinical efficacy, toxicity, and future directions. Curr Res Med Sci. 2024;3(3):53\u201360.","journal-title":"Curr Res Med Sci"},{"issue":"6","key":"3339_CR5","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3390\/cancers16061160","volume":"16","author":"A Ghiaur","year":"2024","unstructured":"Ghiaur A, Doran C, Gaman M-A, Ionescu B, Tatic A, Cirstea M, et al. Acute promyelocytic leukemia: Review of complications related to all-trans retinoic acid and arsenic trioxide therapy. Cancers. 2024;16(6):1160.","journal-title":"Cancers"},{"key":"3339_CR6","doi-asserted-by":"publisher","first-page":"1536388","DOI":"10.3389\/fphar.2025.1536388","volume":"16","author":"J Wen","year":"2025","unstructured":"Wen J, Li A, Wang Z, Guo X, Zhang G, Litzow MR, et al. Hepatotoxicity induced by arsenic trioxide: clinical features, mechanisms, preventive and potential therapeutic strategies. Front Pharmacol. 2025;16:1536388.","journal-title":"Front Pharmacol"},{"issue":"3","key":"3339_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12272-023-01481-y","volume":"47","author":"M Yan","year":"2024","unstructured":"Yan M, Wang H, Wei R, Li W. Arsenic trioxide: Applications, mechanisms of action, toxicity and rescue strategies to date. Arch Pharm Res. 2024;47(3):249\u201371.","journal-title":"Arch Pharm Res"},{"issue":"1","key":"3339_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41420-023-01558-z","volume":"9","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Shen X, Zhi F, Wen Z, Gao Y, Xu J, et al. An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications. Cell Death Discovery. 2023;9(1):266.","journal-title":"Cell Death Discovery"},{"key":"3339_CR9","doi-asserted-by":"publisher","first-page":"1491777","DOI":"10.3389\/fimmu.2025.1491777","volume":"16","author":"MT El-Saadony","year":"2025","unstructured":"El-Saadony MT, Saad AM, Mohammed DM, Korma SA, Alshahrani MY, Ahmed AE, et al. Medicinal plants: bioactive compounds, biological activities, combating multidrug-resistant microorganisms, and human health benefits-a comprehensive review. Front Immunol. 2025;16:1491777.","journal-title":"Front Immunol"},{"issue":"1","key":"3339_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/pr11010083","volume":"11","author":"A Jit\u0103reanu","year":"2022","unstructured":"Jit\u0103reanu A, Trifan A, Vieriu M, Caba I-C, M\u00e2r\u021bu I, Agoroaei L. Current trends in toxicity assessment of herbal medicines: A narrative review. Processes. 2022;11(1):83.","journal-title":"Processes"},{"issue":"5","key":"3339_CR11","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/tox.23090","volume":"36","author":"I Limam","year":"2021","unstructured":"Limam I, Ben Aissa-Fennira F, Essid R, Chahbi A, Kefi S, Mkadmini K, et al. Hydromethanolic root and aerial part extracts from Echium arenarium Guss suppress proliferation and induce apoptosis of multiple myeloma cells through mitochondrial pathway. Environ Toxicol. 2021;36(5):874\u201386.","journal-title":"Environ Toxicol"},{"key":"3339_CR12","doi-asserted-by":"crossref","unstructured":"Moradi A, Aslani F, Boskabady MH, Pahlavan Y, Aslani MR. Effect of Zataria multiflora supplementation on pro-or anti-inflammatory markers: a systematic review and meta-analysis of randomized placebo-controlled trials. Inflammopharmacology. 2025:1\u201316.","DOI":"10.1007\/s10787-025-01668-3"},{"issue":"1","key":"3339_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12906-025-04832-y","volume":"25","author":"N Aryaeian","year":"2025","unstructured":"Aryaeian N, Agh F, Nouri A, Ghoreishy SM, Ahmadi AR, Dehghanseresht N, et al. The effect of Zataria multiflora on respiratory symptoms, pulmonary functions, and oxidative stress parameters: a systematic review and meta-analysis. BMC Complement Med Ther. 2025;25(1):1\u201314.","journal-title":"BMC Complement Med Ther"},{"issue":"1","key":"3339_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/fcp.12331","volume":"32","author":"MR Khazdair","year":"2018","unstructured":"Khazdair MR, Ghorani V, Alavinezhad A, Boskabady MH. Pharmacological effects of Zataria multiflora Boiss L. and its constituents focus on their anti-inflammatory, antioxidant, and immunomodulatory effects. Fundam Clin Pharmacol. 2018;32(1):26\u201350.","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"3339_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3923\/ajps.2010.134.139","volume":"9","author":"AV Gohar","year":"2010","unstructured":"Gohar AV, Mohammadi A, Sharififar F. Role of Zataria multiflora Boiss. Essential oil in regulation of MDM2 and ATM genes expression in rat. Asian J Plant Sci. 2010;9(3):134\u20139.","journal-title":"Asian J Plant Sci"},{"issue":"11","key":"3339_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4103\/2221-1691.389570","volume":"13","author":"R Nosratabadi","year":"2023","unstructured":"Nosratabadi R, Anaeigoudari F, Anaeigoudari A. Therapeutic potential of Zataria multiflora: a narrative review of current evidence. Asian Pac J Trop Biomed. 2023;13(11):451\u20139.","journal-title":"Asian Pac J Trop Biomed"},{"key":"3339_CR17","doi-asserted-by":"publisher","first-page":"1534862","DOI":"10.3389\/fonc.2025.1534862","volume":"15","author":"BH Abdelmonem","year":"2025","unstructured":"Abdelmonem BH, Kamal LT, Wardy LW, Ragheb M, Hanna MM, Elsharkawy M, et al. Non-coding RNAs: emerging biomarkers and therapeutic targets in cancer and inflammatory diseases. Front Oncol. 2025;15:1534862.","journal-title":"Front Oncol"},{"issue":"1","key":"3339_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s43094-022-00413-9","volume":"8","author":"AN Saiyed","year":"2022","unstructured":"Saiyed AN, Vasavada AR, Johar SK. Recent trends in miRNA therapeutics and the application of plant miRNA for prevention and treatment of human diseases. Future J Pharm Sci. 2022;8(1):24.","journal-title":"Future J Pharm Sci"},{"key":"3339_CR19","doi-asserted-by":"crossref","unstructured":"Jurj A, Fontana B, Varani G, Calin GA. Small molecules targeting microRNAs: new opportunities and challenges in precision cancer therapy. Trends cancer. 2024.","DOI":"10.1016\/j.trecan.2024.06.006"},{"issue":"25","key":"3339_CR20","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1038\/onc.2014.274","volume":"34","author":"R Su","year":"2015","unstructured":"Su R, Lin H, Zhang X, Yin X, Ning H, Liu B, et al. MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets. Oncogene. 2015;34(25):3226\u201339.","journal-title":"Oncogene"},{"issue":"4","key":"3339_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3892\/ijo.2023.5556","volume":"63","author":"J Li","year":"2023","unstructured":"Li J, Shen J, Zhao Y, Du F, Li M, Wu X, et al. Role of miR-181a-5p in cancer. Int J Oncol. 2023;63(4):108.","journal-title":"Int J Oncol"},{"issue":"1","key":"3339_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12943-016-0518-2","volume":"15","author":"C-H Yeh","year":"2016","unstructured":"Yeh C-H, Moles R, Nicot C. Clinical significance of microRNAs in chronic and acute human leukemia. Mol Cancer. 2016;15(1):37.","journal-title":"Mol Cancer"},{"issue":"2","key":"3339_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12032-023-02278-1","volume":"41","author":"M Bansal","year":"2024","unstructured":"Bansal M, Ansari S, Verma M. Role of miRNAs to control the progression of Chronic Myeloid Leukemia by their expression levels. Med Oncol. 2024;41(2):55.","journal-title":"Med Oncol"},{"key":"3339_CR24","doi-asserted-by":"publisher","first-page":"708765","DOI":"10.3389\/fonc.2021.708765","volume":"11","author":"K Otmani","year":"2021","unstructured":"Otmani K, Lewalle P. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Front Oncol. 2021;11:708765.","journal-title":"Front Oncol"},{"key":"3339_CR25","doi-asserted-by":"publisher","first-page":"100669","DOI":"10.1016\/j.jbior.2019.100669","volume":"75","author":"V Balatti","year":"2020","unstructured":"Balatti V, Croce CM. MicroRNA dysregulation and multi-targeted therapy for cancer treatment. Adv Biol Regul. 2020;75:100669.","journal-title":"Adv Biol Regul"},{"key":"3339_CR26","first-page":"100647","volume":"33","author":"W Zhao","year":"2022","unstructured":"Zhao W, Gupta A, Krawczyk J, Gupta S. The miR-17-92 cluster: Yin and Yang in human cancers. Cancer Treat Res Commun. 2022;33:100647.","journal-title":"Cancer Treat Res Commun"},{"issue":"10","key":"3339_CR27","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41419-019-1964-8","volume":"10","author":"S Ganesan","year":"2019","unstructured":"Ganesan S, Palani HK, Lakshmanan V, Balasundaram N, Alex AA, David S, et al. Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia. Cell Death Dis. 2019;10(10):736.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3339_CR28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/s12967-021-03174-w","volume":"19","author":"W Yan","year":"2021","unstructured":"Yan W, Song L, Wang H, Yang W, Hu L, Yang Y. Extracellular vesicles carrying miRNA-181b-5p affects the malignant progression of acute lymphoblastic leukemia. J Translational Med. 2021;19(1):511.","journal-title":"J Translational Med"},{"issue":"4","key":"3339_CR29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3892\/ol.2022.13450","volume":"24","author":"H Lu","year":"2022","unstructured":"Lu H, Ding Y, Dong Y, Luo X, Wang X, Xiu B, et al. MicroRNA-181b-5p insufficiency predicts treatment response failure risk and unfavorable event-free survival as well as overall survival in acute myeloid leukemia patients. Oncol Lett. 2022;24(4):330.","journal-title":"Oncol Lett"},{"issue":"1","key":"3339_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10238-025-01763-3","volume":"25","author":"H Kariminejad-Farsangi","year":"2025","unstructured":"Kariminejad-Farsangi H, Mirzaee Khalilabadi R, Afgar A, Mirzaie M, Mardani Valandani H. Microvesicle inhibition enhances the therapeutic effects of ATRA in acute promyelocytic leukemia cells via changes in miRNAs: the promising antileukemic potential of imipramine. Clin Experimental Med. 2025;25(1):217.","journal-title":"Clin Experimental Med"},{"issue":"1","key":"3339_CR31","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.clnves.2025.100007","volume":"1","author":"S Hou","year":"2025","unstructured":"Hou S, Liu J, Zhu Y. Multi-omics advances for molecular characterization, precision medicine, and prognostic implications in leukemia. Cell Invest. 2025;1(1):100007.","journal-title":"Cell Invest"},{"issue":"22","key":"3339_CR32","doi-asserted-by":"publisher","first-page":"5756","DOI":"10.3390\/ijms20225756","volume":"20","author":"A Zebisch","year":"2019","unstructured":"Zebisch A, Caraffini V, Sill H. RAF kinase inhibitor protein in myeloid leukemogenesis. Int J Mol Sci. 2019;20(22):5756.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3339_CR33","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/17474086.2022.2108015","volume":"15","author":"M He","year":"2022","unstructured":"He M, Jia Y, Wang Y, Cai X. Dysregulated MAPK signaling pathway in acute myeloid leukemia with RUNX1 mutations. Expert Rev Hematol. 2022;15(8):769\u201379.","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"3339_CR34","doi-asserted-by":"publisher","first-page":"11898","DOI":"10.1080\/21655979.2021.1999552","volume":"12","author":"H Tian","year":"2021","unstructured":"Tian H, Qiang T, Wang J, Ji L, Li B. Simvastatin regulates the proliferation, apoptosis, migration and invasion of human acute myeloid leukemia cells via miR-19a-3p\/HIF-1\u03b1 axis. Bioengineered. 2021;12(2):11898\u2013908.","journal-title":"Bioengineered"},{"issue":"7","key":"3339_CR35","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/leu.2011.66","volume":"25","author":"LS Steelman","year":"2011","unstructured":"Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, B\u00e4secke J, et al. Roles of the Ras\/Raf\/MEK\/ERK pathway in leukemia therapy. Leukemia. 2011;25(7):1080\u201394.","journal-title":"Leukemia"},{"issue":"2","key":"3339_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41568-023-00650-x","volume":"24","author":"M Riaud","year":"2024","unstructured":"Riaud M, Maxwell J, Soria-Bretones I, Dankner M, Li M, Rose AA. The role of CRAF in cancer progression: from molecular mechanisms to precision therapies. Nat Rev Cancer. 2024;24(2):105\u201322.","journal-title":"Nat Rev Cancer"},{"key":"3339_CR37","doi-asserted-by":"publisher","first-page":"101479","DOI":"10.1016\/j.rineng.2023.101479","volume":"20","author":"MH Ashoub","year":"2023","unstructured":"Ashoub MH, Amiri M, Razavi R, Dawi EA, Farsinejad A, Divsalar F, et al. Induction of ferroptosis cell death in acute promyelocytic leukemia cell lines (NB4 and HL-60) using hydrothermally synthesized ZnO NPs in the presence of black cardamom extract. Results Eng. 2023;20:101479.","journal-title":"Results Eng"},{"key":"3339_CR38","doi-asserted-by":"publisher","first-page":"S355","DOI":"10.1016\/S2152-2650(22)01493-8","volume":"22","author":"H Ababneh","year":"2022","unstructured":"Ababneh H, Frigault M, Patel C. ABCL-044 Clinical Outcomes of Commercial CD19-Targeted CAR T-Cell Therapy in Patients With Secondary Central Nervous System Lymphoma. Clin Lymphoma Myeloma Leuk. 2022;22:S355.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"3339_CR39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s12032-025-02815-0","volume":"42","author":"MH Ashoub","year":"2025","unstructured":"Ashoub MH, Ahmadi M, Heydaryan K, Dawi EA, Amiri M. Dual-responsive magnetic and pH-sensitive hydrogel beads for controlled cisplatin delivery in glioblastoma cells. Med Oncol. 2025;42(7):247.","journal-title":"Med Oncol"},{"issue":"7","key":"3339_CR40","doi-asserted-by":"publisher","first-page":"103792","DOI":"10.1016\/j.xphs.2025.103792","volume":"114","author":"MH Ashoub","year":"2025","unstructured":"Ashoub MH, Golestani A, Amiri M, Razavi R, Farsinejad A. pH-sensitive sulfasalazine release from green-synthesized mesoporous Fe3O4@SiO2 nanocomposites using Opuntia ficus-indica extract. J Pharm Sci. 2025;114(7):103792.","journal-title":"J Pharm Sci"},{"issue":"1","key":"3339_CR41","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s11033-025-11106-w","volume":"52","author":"S Mostajeran","year":"2025","unstructured":"Mostajeran S, Ehsan M, Lashkari M, Valandani HM, Fatemi A, Bazi A, et al. Zataria multiflora extract enhances imatinib-induced cytotoxicity in chronic myeloid leukemia and multiple myeloma cells. Mol Biol Rep. 2025;52(1):1027.","journal-title":"Mol Biol Rep"},{"key":"3339_CR42","doi-asserted-by":"crossref","unstructured":"Ashoub MH, Amiri M, Fatemi A, Farsinejad A. Evaluation of ferroptosis-based anti-leukemic activities of ZnO nanoparticles synthesized by a green route against Pre-B acute lymphoblastic leukemia cells (Nalm-6 and REH). Heliyon. 2024;10(17).","DOI":"10.1016\/j.heliyon.2024.e36608"},{"issue":"4","key":"3339_CR43","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1007\/s10528-023-10565-9","volume":"62","author":"F Yari","year":"2024","unstructured":"Yari F, Ashoub MH, Amirizadeh N, Nikougoftar M, valandani HM, Khalilabadi RM. Differential Expression of the hTERT Gene in Umbilical Cord-Derived Mesenchymal Stem Cells Cocultured with B Cell Precursor Leukemia Cell Microparticles or CD41+\/CD61\u2009+\u2009Platelet Microparticles. Biochem Genet. 2024;62(4):2796\u2013809.","journal-title":"Biochem Genet"},{"issue":"1","key":"3339_CR44","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1038\/s41598-025-85329-z","volume":"15","author":"MH Ashoub","year":"2025","unstructured":"Ashoub MH, Afgar A, Farsinejad A, Razavi R, Anvari S, Fatemi A. siRNA-mediated inhibition of hTERT enhances the effects of curcumin in promoting cell death in precursor-B acute lymphoblastic leukemia cells: an in silico and in vitro study. Sci Rep. 2025;15(1):3083.","journal-title":"Sci Rep"},{"issue":"1","key":"3339_CR45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11033-023-09087-9","volume":"51","author":"M Katoueezadeh","year":"2024","unstructured":"Katoueezadeh M, Maleki P, Torabizadeh SA, Farsinejad A, Khalilabadi RM, Valandani HM, et al. Combinatorial targeting of telomerase and DNA-PK induces synergistic apoptotic effects against Pre-B acute lymphoblastic leukemia cells. Mol Biol Rep. 2024;51(1):163.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"3339_CR46","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.fmre.2023.04.012","volume":"5","author":"X Wang","year":"2025","unstructured":"Wang X, Tong Y, Xun T, Feng H, Lei Y, Li Y, et al. Functions, mechanisms, and therapeutic implications of noncoding RNA in acute myeloid leukemia. Fundamental Res. 2025;5(4):1781\u201394.","journal-title":"Fundamental Res"},{"key":"3339_CR47","doi-asserted-by":"crossref","unstructured":"Anelli L, Zagaria A, Specchia G, Musto P, Albano F. Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers. Int J Mol Sci. 2021;22(13).","DOI":"10.3390\/ijms22137156"},{"issue":"24","key":"3339_CR48","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1101\/gad.1861409","volume":"23","author":"V Olive","year":"2009","unstructured":"Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009;23(24):2839\u201349.","journal-title":"Genes Dev"},{"issue":"4","key":"3339_CR49","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3390\/genes16040446","volume":"16","author":"A Wi\u015bnik","year":"2025","unstructured":"Wi\u015bnik A, Jarych D, Krawiec K, Strza\u0142ka P, Potocka N, Czemerska M, et al. Role of MicroRNAs in Acute Myeloid Leukemia. Genes. 2025;16(4):446.","journal-title":"Genes"},{"issue":"1","key":"3339_CR50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/ijlh.14211","volume":"46","author":"R Chandraprabha Vineetha","year":"2024","unstructured":"Chandraprabha Vineetha R, Anitha Geetha Raj J, Devipriya P, Sreelatha Mahitha M, Hariharan S. MicroRNA-based therapies: Revolutionizing the treatment of acute myeloid leukemia. Int J Lab Hematol. 2024;46(1):33\u201341.","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"3339_CR51","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/hemato6030030","volume":"6","author":"M Abdelkarim","year":"2025","unstructured":"Abdelkarim M, Limam I, Berred E, Kharrat R, Sola B, Ben Aissa-Fennira F. miR-429 Acts as a Tumor Suppressor in Multiple Myeloma by Regulating Cell Proliferation. Hemato. 2025;6(3):30.","journal-title":"Hemato"},{"key":"3339_CR52","doi-asserted-by":"publisher","first-page":"101522","DOI":"10.1016\/j.tranon.2022.101522","volume":"25","author":"S Teng-Fei","year":"2022","unstructured":"Teng-Fei S, Diyaer A, Hong-Ming Z, Xin-Jie C, Wen-Fang W, Yu-Bing Z, et al. Evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: a real-world analysis of 1105 patients over the last three decades. Translational Oncol. 2022;25:101522.","journal-title":"Translational Oncol"},{"key":"3339_CR53","doi-asserted-by":"publisher","first-page":"1062524","DOI":"10.3389\/fonc.2022.1062524","volume":"12","author":"SG Iyer","year":"2023","unstructured":"Iyer SG, Elias L, Stanchina M, Watts J. The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions. Front Oncol. 2023;12:1062524.","journal-title":"Front Oncol"},{"key":"3339_CR54","doi-asserted-by":"crossref","unstructured":"de Almeida TD, Evangelista FCG, Sabino AP. Acute Promyelocytic Leukemia (APL): A Review of the Classic and Emerging Target Therapies towards Molecular Heterogeneity. Future Pharmacol. 2023;3(1).","DOI":"10.3390\/futurepharmacol3010012"},{"issue":"13","key":"3339_CR55","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1080\/10428194.2019.1613540","volume":"60","author":"M Stahl","year":"2019","unstructured":"Stahl M, Tallman MS. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. Leuk Lymphoma. 2019;60(13):3107\u201315.","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"3339_CR56","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022\u201343.","journal-title":"Oncotarget"},{"issue":"7","key":"3339_CR57","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.3390\/biomedicines13071652","volume":"13","author":"Z Zhong","year":"2025","unstructured":"Zhong Z, Yao R, Duan Y, Ouyang C, Du Z, Li L, et al. Advances and Challenges in Targeted Therapy and Its Combination Strategies for Leukemia. Biomedicines. 2025;13(7):1652.","journal-title":"Biomedicines"},{"issue":"1","key":"3339_CR58","doi-asserted-by":"publisher","first-page":"12657","DOI":"10.1038\/s41598-022-16943-4","volume":"12","author":"M Lashkari","year":"2022","unstructured":"Lashkari M, Fatemi A, Valandani HM, Khalilabadi RM. Promising anti-leukemic effect of Zataria multiflora extract in combination with doxorubicin to combat acute lymphoblastic leukemia cells (Nalm-6) (in vitro and in silico). Sci Rep. 2022;12(1):12657.","journal-title":"Sci Rep"},{"issue":"6","key":"3339_CR59","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","volume":"35","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non\u2013high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35(6):605\u201312.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3339_CR60","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1007\/s00277-024-06038-7","volume":"103","author":"F Efficace","year":"2024","unstructured":"Efficace F, Sparano F, Breccia M, Greco C, Carluccio P, Borlenghi E, et al. Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial. Ann Hematol. 2024;103(12):5341\u20139.","journal-title":"Ann Hematol"},{"key":"3339_CR61","doi-asserted-by":"crossref","unstructured":"Mafi A, Rismanchi H, Gholinezhad Y, Mohammadi MM, Mousavi V, Hosseini SA et al. Melatonin as a regulator of apoptosis in leukaemia: molecular mechanism and therapeutic perspectives. Front Pharmacol. 2023;Volume 14\u20132023.","DOI":"10.3389\/fphar.2023.1224151"},{"key":"3339_CR62","doi-asserted-by":"crossref","unstructured":"Merhi F, Dauzonne D, Bauvois B. Implementation of Natural Products and Derivatives in Acute Myeloid Leukemia Management: Current Treatments, Clinical Trials and Future Directions. Cancers (Basel). 2026;18(2).","DOI":"10.3390\/cancers18020185"},{"issue":"3","key":"3339_CR63","first-page":"1895","volume":"36","author":"F Nemati","year":"2015","unstructured":"Nemati F, Janitermi M. Cytotoxic effect of Zataria multiflora on breast cancer cell line (MCF-7) and normal fibroblast cells. Cumhuriyet \u00dcniversitesi Fen-Edebiyat Fak\u00fcltesi Fen Bilimleri Dergisi. 2015;36(3):1895\u2013904.","journal-title":"Cumhuriyet \u00dcniversitesi Fen-Edebiyat Fak\u00fcltesi Fen Bilimleri Dergisi"},{"issue":"3","key":"3339_CR64","first-page":"1876","volume":"36","author":"F Nemati","year":"2015","unstructured":"Nemati F, Janitermi M, Mohammadpour G. Cytotoxic effect of Zataria multiflora on gastric cancer cell line (AGS) and normal fibroblast cells. Cumhuriyet \u00dcniversitesi Fen-Edebiyat Fak\u00fcltesi Fen Bilimleri Dergisi. 2015;36(3):1876\u201384.","journal-title":"Cumhuriyet \u00dcniversitesi Fen-Edebiyat Fak\u00fcltesi Fen Bilimleri Dergisi"},{"key":"3339_CR65","unstructured":"Janitermi M, Nemati F. Cytotoxic effect of Zataria multiflora on cervical cancer cell line (HeLa) and normal fibroblast cells. Fen Bilimleri Dergisi (CFD). 2015;36(3)."},{"issue":"9","key":"3339_CR66","doi-asserted-by":"publisher","first-page":"e70936","DOI":"10.1002\/fsn3.70936","volume":"13","author":"AM Noman","year":"2025","unstructured":"Noman AM, Sultan MT, Zafar S, Maaz M, Mazhar A, Hussain M, et al. Thymol and Carvacrol: Molecular Mechanisms, Therapeutic Potential, and Synergy With Conventional Therapies in Cancer Management. Food Sci Nutr. 2025;13(9):e70936.","journal-title":"Food Sci Nutr"},{"key":"3339_CR67","doi-asserted-by":"crossref","unstructured":"Sampaio LA, Pina LTS, Serafini MR, Tavares DS, Guimar\u00e3es AG. Antitumor Effects of Carvacrol and Thymol: A Systematic Review. Front Pharmacol. 2021;Volume 12\u20132021.","DOI":"10.3389\/fphar.2021.702487"},{"key":"3339_CR68","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fmed.2015.00064","volume":"2","author":"CS Fuziwara","year":"2015","unstructured":"Fuziwara CS, Kimura ET. Insights into regulation of the miR-17-92 cluster of miRNAs in cancer. Front Med. 2015;2:64.","journal-title":"Front Med"},{"issue":"2","key":"3339_CR69","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1182\/blood-2008-05-158139","volume":"113","author":"A Saumet","year":"2009","unstructured":"Saumet A, Vetter G, Bouttier M, Portales-Casamar E, Wasserman WW, Maurin T, et al. Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood. 2009;113(2):412\u201321.","journal-title":"Blood"},{"issue":"2","key":"3339_CR70","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3390\/cancers12020496","volume":"12","author":"S Hatzl","year":"2020","unstructured":"Hatzl S, Perfler B, Wurm S, Uhl B, Quehenberger F, Ebner S, et al. Increased expression of micro-RNA-23a mediates chemoresistance to cytarabine in acute myeloid leukemia. Cancers. 2020;12(2):496.","journal-title":"Cancers"},{"issue":"49","key":"3339_CR71","doi-asserted-by":"publisher","first-page":"7287","DOI":"10.1038\/sj.onc.1204863","volume":"20","author":"MJ Roussel","year":"2001","unstructured":"Roussel MJ, Lanotte M. Maturation sensitive and resistant t (15; 17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes. Oncogene. 2001;20(49):7287\u201391.","journal-title":"Oncogene"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03339-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03339-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03339-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:03:22Z","timestamp":1788930202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03339-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":71,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["3339"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03339-x","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (cell line-based study; no human subjects except for PBMC donation with informed consent).","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethical Committee of Kerman University of Medical Sciences (Approval Code: IR.KMU.REC.1401.015; Registration Number: 400000607).","order":4,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"226"}}